A central event that underlies the etiology of Alzheimer's disease (AD) is the self-assembly of the amyloid-β (Aβ) peptide into aggregates termed amyloids. Increasing evidence implicates soluble prefibrillar Aβ oligomers in the neurodegeneration and synaptic dysfunction in AD. Recently we introduced a new class of highly promising antagonists of Aβ amyloidogenesis: designed cell-penetrating peptides (CPPs). These CPPs combine the attractive intrinsic properties of peptides (high target specificity and selectivity, biocompatibility, biodegradability, and ease and low cost of production) with potent therapeutic effects (inhibition of Aβ oligomerization, fiber formation, and neurotoxicity) and highly efficient delivery (to target cells and subcellular organelles).
Get full access to this article
View all access options for this article.
References
1.
BoulikasT. (1994). Putative nuclear localization signals (NLS) in protein transcription factors. J Cell, Biochem, DOI: 10.1002/jcb.240550106.
2.
BrothersH.M., GosztylaM.L., and RobinsonS.R. (2018). The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer's disease. Front Aging Neurosci 10,118.
3.
CaugheyB., and LansburyP.T. (2003). Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Ann Rev Neurosci, 26, 267–298.
4.
ChenK., LuH., GaoT., XueX., WangC., and MiaoF. (2016). Synergic interaction between amyloid precursor protein and neural cell adhesion molecule promotes neurite outgrowth. Oncotarget, 7, 14199–14206.
5.
ChenK.-P., and DouF. (2012). Selective interaction of amyloid precursor protein with different isoforms of neural cell adhesion molecule. J Mol Neurosci, 46, 203–209.
6.
ChenS., YadavS.P., and SurewiczW.K. (2010). Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role of N-terminal residues. J Biol Chem, 285, 26377–26383.
7.
ChitiF., and DobsonC.M. (2006). Protein misfolding, functional amyloid, and human disease. Ann Rev Biochem, 75, 333–366.
8.
CitronM. (2010). Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov, 9, 387–398.
9.
DodelR., HampelH., DepboyluC., LinS., GaoF., SchockS., et al. (2002). Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol, 52, 253–256.
10.
EdwardsA.B., AndertonR.S., KnuckeyN.W., and MeloniB.P. (2017). Characterisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model. Mol Cell Biochem, 426, 75–85.
FosgerauK., and HoffmannT. (2015). Peptide therapeutics: current status and future directions. Drug Discov Today, 20, 122–128.
13.
FrozzaR.L., LourencoM.V., and De FeliceF.G. (2018). Challenges for Alzheimer's disease therapy: insights from novel mechanisms beyond memory defects. Front Neurosci 12,37.
14.
GiulianD., HaverkampL.J., YuJ., KarshinW., TomD., LiJ., et al. (1998). The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. J Biol Chem, 273, 29719–29726.
15.
GoedertM., and SpillantiniM.G. (2006). A century of Alzheimer's disease. Science (New York, NY), 314, 777–781.
16.
HaassC., KaetherC., ThinakaranG., and SisodiaS. (2012). Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2,a006270.
17.
HachiyaN.S., YamadaM., WatanabeK., JozukaA., OhkuboT., SanoK., et al. (2005). Mitochondrial localization of cellular prion protein (PrPC) invokes neuronal apoptosis in aged transgenic mice overexpressing PrPC. Neurosci Lett, 374, 98–103.
18.
Henning-KnechtelA., KumarS., WallinC., KrólS., WärmländerS.K.T.S., JarvetJ., EspositoG., et al. (2020). Designed cell-penetrating peptide inhibitors of amyloid-beta aggregation and cytotoxicity. Cell Rep Phys Sci 1,100014.
19.
HilbichC., Kisters-WoikeB., ReedJ., MastersC.L., and BeyreutherK. (1992). Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J Mol Biol, 228, 460–473.
20.
JanA., HartleyD.M., and LashuelH.A. (2010). Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research. Nat Protocols, 5, 1186–1209.
21.
JarrettJ.T., BergerE.P., and LansburyP.T. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry, 32, 4693–4697.
22.
KrautwaldS., DewitzC., FändrichF., and KunzendorfU. (2016). Inhibition of regulated cell death by cell-penetrating peptides. Cell Mol Life Sci, 73, 2269–2284.
23.
KumarS., Henning-KnechtelA., ChehadeI., MagzoubM., and HamiltonA.D. (2017). Foldamer-mediated structural rearrangement attenuates Aβ oligomerization and cytotoxicity. J Am Chem Soc, 139, 17098–17108.
24.
KumarS., Henning-KnechtelA., MagzoubM., and HamiltonA.D. (2018). Peptidomimetic-based multidomain targeting offers critical evaluation of Aβ structure and toxic function. J Am Chem Soc, 140, 6562–6574.
25.
LindgrenJ., WahlströmA., DanielssonJ., MarkovaN., EkbladC., GräslundA., et al. (2010). N-terminal engineering of amyloid-β-binding affibody molecules yields improved chemical synthesis and higher binding affinity. Protein Sci, 19, 2319–2329.
26.
LöfgrenK., WahlströmA., LundbergP., LangelU., GräslundA., and BedecsK. (2008). Antiprion properties of prion protein-derived cell-penetrating peptides. FASEB J, 22, 2177–2184.
27.
LoweT.L., StrzelecA., KiesslingL.L., and MurphyR.M. (2001). Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry, 40, 7882–7889.
28.
LundbergP., MagzoubM., LindbergM., HällbrinkM., JarvetJ., ErikssonL.E., et al. (2002). Cell membrane translocation of the N-terminal (1-28) part of the prion protein. Biochem Biophys Res Commun, 299, 85–90.
29.
LustbaderJ.W., CirilliM., LinC., XuH.W., TakumaK., WangN., et al. (2004). ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science (New York, NY), 304, 448–452.
30.
MagzoubM., and GräslundA. (2004). Cell-penetrating peptides: [corrected] from inception to application. Quart Rev Biophys, 37, 147–195.
31.
MagzoubM., and MirankerA.D. (2012). Concentration-dependent transitions govern the subcellular localization of islet amyloid polypeptide. FASEB J, 26, 1228–1238.
32.
MagzoubM., SandgrenS., LundbergP., OgleckaK., LiljaJ., WittrupA., et al. (2006). N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis. Biochem Biophys Res Commun, 348, 379–385.
33.
MukundanV., MaksoudianC., VogelM.C., ChehadeI., KatsiotisM.S., AlhassanS.M., et al. (2017). Cytotoxicity of prion protein-derived cell-penetrating peptides is modulated by PH but independent of amyloid formation. Arch Biochem Biophys, 613, 31–42.
34.
NakamuraK., NemaniV.M., AzarbalF., SkibinskiG., LevyJ.M., EgamiK., et al. (2011). Direct membrane association drives mitochondrial fission by the parkinson disease-associated protein alpha-synuclein. J Biol Chem, 286, 20710–20726.
35.
NeculaM., BreydoL., MiltonS., KayedR., van der VeerW.E., ToneP., et al. (2007). Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization. Biochemistry, 46, 8850–8860.
36.
NeddenriepB., CalcianoA., ContiD., SauveE., PatersonM., BrunoE., et al. (2011). Short peptides as inhibitors of amyloid aggregation. Open Biotechnol J, 5, 39–46.
37.
OgleckaK., LundbergP., MagzoubM., Göran ErikssonL.E., LangelU., and GräslundA. (2008). Relevance of the N-terminal NLS-like sequence of the prion protein for membrane perturbation effects. Biochim Biophys Acta, 1778, 206–213.
38.
PoogaM., and Langel, Ü. (2015). Classes of cell-penetrating peptides. In Cell-Penetrating Peptides: Methods and Protocols (Methods in Molecular Biology). Ü. Langel, and Ü. Langel, eds. (Humana Press, New York, NY), pp. 3–28.
39.
RajuM., SanthoshkumarP., and SharmaK.K. (2018). Cell-penetrating chaperone peptide prevents protein aggregation and protects against cell apoptosis. Adv Biosyst 2,1700095.
40.
RezguiR., BlumerK., Yeoh-TanG., TrexlerA.J., and MagzoubM. (2016). Precise quantification of cellular uptake of cell-penetrating peptides using fluorescence-activated cell sorting and fluorescence correlation spectroscopy. Biochim Biophys Acta Biomembr, 1858(7, Part A), 1499–1506.
41.
RibaričS. (2018). Peptides as potential therapeutics for Alzheimer's disease. Molecules (Basel, Switzerland) 23,E283.
42.
RoherA.E., LowensonJ.D., ClarkeS., WolkowC., WangR., CotterR.J., et al. (1993). Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem, 268, 3072–3083.
43.
SantuccioneA., SytnykV., Leshchyns'kaI., and SchachnerM. (2005). Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate P59fyn and to enhance neurite outgrowth. J Cell Biol, 169, 341–354.
44.
Schmitt-UlmsG., LegnameG., BaldwinM.A., BallH.L., BradonN., BosqueP.J., et al. (2001). Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. J Mol Biol, 314, 1209–1225.
45.
SelkoeD.J. (1991). The molecular pathology of Alzheimer's disease. Neuron, 6, 487–498.
SöderbergK.L., GuterstamP., LangelU., and GräslundA. (2014). Targeting prion propagation using peptide constructs with signal sequence motifs. Arch Biochem Biophys, 564, 254–261.
49.
SotoC., SigurdssonE.M., MorelliL., KumarR.A., CastañoE.M., and FrangioneB. (1998). Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med, 4, 822–826.
50.
SundeM., and BlakeC.C. (1998). From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Quart Rev Biophys, 31, 1–39.
51.
TiimanA., KrishtalJ., PalumaaP., and TõuguV. (2015). In vitro fibrillization of Alzheimer's amyloid-β peptide (1-42). AIP Adv 5,092401.
52.
TjernbergL.O., NäslundJ., LindqvistF., JohanssonJ., KarlströmA.R., ThybergJ., et al. (1996). Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem, 271, 8545–8548.
53.
TownsendM., ShankarG.M., MehtaT., WalshD.M., and SelkoeD.J. (2006). Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol, 572(Pt 2), 477–492.
54.
TsomaiaN. (2015). Peptide therapeutics: targeting the undruggable space. Eur J Med Chem, 94, 459–470.
55.
van der KantR., and GoldsteinL.S.B. (2015). Cellular functions of the amyloid precursor protein from development to dementia. Dev Cell, 32, 502–515.
56.
WadiaJ.S., SchallerM., WilliamsonR.A., and DowdyS.F. (2008). Pathologic prion protein infects cells by lipid-raft dependent macropinocytosis. PLoS One 3,e3314.
57.
WärmländerS., TiimanA., AbeleinA., LuoJ., JarvetJ., SöderbergK.L., et al. (2013). Biophysical studies of the amyloid beta-peptide: interactions with metal ions and small molecules. Chembiochem, 14, 1692–1704.
58.
WhiteJ.A., ManelliA.M., HolmbergK.H., Van EldikL.J., and LaduM.J. (2005). Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis, 18, 459–465.
59.
WoldetsadikA.D., VogelM.C., RabehW.M., and MagzoubM. (2017). Hexokinase II-derived cell-penetrating peptide targets mitochondria and triggers apoptosis in cancer cells. FASEB J, 31, 2168–2184.
60.
YamA.Y., WangX., GaoC.M., ConnollyM.D., ZuckermannR.N., BleuT., et al. (2011). A universal method for detection of amyloidogenic misfolded proteins. Biochemistry, 50, 4322–4329.
61.
YounanN.D., SarellC.J., DaviesP., BrownD.R., and VilesJ.H. (2013). The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers. FASEB J, 27, 1847–1858.
